Trial Profile

Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NRG 5051 (Primary)
Indications Amyotrophic lateral sclerosis; Neurodegenerative disorders; Parkinson's disease
Focus Adverse reactions; First in man; Pharmacodynamics
Sponsors NRG Therapeutics

01 Dec 2025 Status changed from planning to recruiting.
08 Sep 2025 According to a NRG Therapeutics media release,NRG5051 has completed IND-enabling studies and is on track to enter first-in-human clinical studies in early 2026.
08 Sep 2025 According to a NRG Therapeutics media release, company has announced Oversubscribed 50m pounds Series B Financing to develope clinical proof of concept in ALS/MND with NRG5051.while also generating meaningful clinical data in Parkinsons patients through a Phase 1b study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com